Gentian Diagnostics ASA GENT
Oslo Børs · Healthcare · Medical Devices
39.10 NOK
+1.3%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Gentian Diagnostics
| NOK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 102 | 135 | 152 | 176 |
| EBITDA | −12 | −0 | 30 | 35 |
| Net income | −24 | −11 | 45 | 13 |
| Balance sheet | ||||
| Equity | 154 | 147 | 194 | 205 |
| Total debt | 15 | 13 | 10 | 23 |
| Cash | 82 | 88 | 85 | 106 |
| Net debt | −66 | −75 | −75 | −83 |
| Ratios and per share | ||||
| EBITDA margin | −11.9% | −0.0% | 19.5% | 20.1% |
| Profit margin | −23.2% | −7.9% | 29.8% | 7.5% |
| Return on equity | −15.3% | −7.3% | 23.3% | 6.5% |
| Earnings/share (NOK) | −1.53 | −0.69 | 2.94 | 0.86 |
| Book value/share (NOK) | 10.00 | 9.51 | 12.58 | 13.29 |
| Shares outstanding (M) | 15 | 15 | 15 | 15 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 45.5 |
| P/B | 2.9 |
| EV / EBITDA | 14.7 |
| Net debt / EBITDA | −2.3 |
| Return on equity | 6.5% |
| Profit margin | 7.5% |
| Beta 1Y | −0.01 |
| Revenue growth 1Y | +16.1% |
| Revenue CAGR 3Y | +20.2% |
| ROE avg. 3Y | 7.5% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
| 2026 | 0.60 |
| 2025 | 0.40 |
Not investment advice. Figures may contain errors from the data source.